Pharmaceuticals & Fine Chemicals
Vacuum evaporation (40–80°C, 30–200 mbar abs) and crystallization systems for API production, solvent recovery (MeOH / EtOH / DCM / THF / toluene) and fine-chemical purification — GMP-grade SS316L construction (Ra ≤ 0.4–0.8 µm), CIP / SIP design, polymorph control and documentation (3.1B, IQ/OQ) aligned with FDA / EMA / NMPA audit expectations.
Why Pharmaceutical Crystallization Is Different
Pharma combines thermal sensitivity, polymorph control, GMP documentation and a solvent diversity few other industries face. The crystallizer is not just a unit operation — it defines the API’s physical form and the regulatory submission.
Thermally Sensitive APIs
Many APIs degrade, racemize or discolor at atmospheric boiling. Vacuum evaporation preserves thermal stability — the temperature ceiling is a process specification, not an engineering preference.
- Degradation, racemization and color formation accelerate at atmospheric boiling
- Ceiling set by API thermal data: DSC, TGA, forced-degradation study
Polymorph & Crystal Habit Control
APIs frequently exhibit polymorphism — supersaturation profile, cooling ramp, seeding, residence time and agitation define which form you ship.
- Carbamazepine: 4 known forms · sulfathiazole: 5 · ritonavir: 2, with drastically different bioavailability
- These are process-engineering decisions, fixed in the pilot phase by DoE study
GMP Compliance & Audit Trail
Documentation is part of the deliverable, not a side task — from material certification to FAT protocol.
- Material certificates 3.1B EN 10204; welder qualifications to ASME IX or equivalent
- Hygienic design: slope-for-drainage ≥ 3°, no dead legs > 3D, sanitary clamp / ASME-BPE connections
- Instrument calibration traceable to NIST / NPL
Diverse, Flammable Solvents — Recovery Duty
Methanol, ethanol, DCM CH₂Cl₂, toluene, THF and solvent mixtures each bring their own material, vacuum, recovery and explosion-proofing requirements. A “standard” pharmaceutical crystallizer does not exist — the solvent defines the engineering, and the mother liquor defines the yield.
- Solvent defines materials, vacuum system and explosion-proofing scope
- Azeotrope behavior governs the recovery column design
- Residual product in mother liquor is the yield lever (Solution 03)
Typical Applications in Pharmaceuticals & Fine Chemicals
Common feed streams in pharmaceutical and fine chemical production, with the technology route typically considered for first-pass screening.
API Crystallization
Final-step API isolation — polymorph-critical, thermally limited, PSD-specified.
- Thermal sensitivity above 60–80°C for many APIs
- Route: vacuum + cooling crystallization with seeding
- SS316L product contact, Ra ≤ 0.4 µm polish for final API surfaces
Intermediates & Fine Chemical Crystallization
Specialty intermediates and agro actives — purity and PSD specification without API-level GMP documentation scope.
- Purity > 99% typical product specification
- Route: DTB / FC crystallizer by solubility behavior
- SS316L / Hastelloy by solvent and chloride profile
Solvent Recovery from Mother Liquors
Mother-liquor distillation and solvent recycle — water–organic separation governed by azeotrope behavior.
- Azeotropes: MeOH / acetone / water systems; DCM–water
- Route: vacuum evaporator / distillation column
- SS316L / Hastelloy C-276 for chlorinated duty
Pharmaceutical Wastewater ZLD
Process effluent and equipment wash water — high-COD, low-TDS profile with residual solvent and trace API.
- Trace API at µg/L levels — destruction or recovery route ahead of the brine train
- Solvent stripping pre-treatment; mixed-solvent saline streams routed to brine crystallization
- Route: pre-treat + ZLD; Hastelloy / Titanium by chloride profile
API Crystallization Methods & Indicative Route
Four supersaturation-generation methods cover most API isolation duties. The indicative flow below shows where solvent recovery plugs in.
Simplified PFD for indicative routing only. Polymorph control requires dedicated design-of-experiments (DoE) in the pilot phase. Solvent recovery column design depends on the solvent mixture and azeotrope behavior. Mother-liquor concentrate goes to incineration or further recovery, per project.
Crystal Form Control Strategy
The crystallizer is engineered to reproduce a verified process envelope — never to invent one.
Polymorph Screening
Customer-side DoE: carbamazepine 4 forms, sulfathiazole 5, ritonavir 2 — form selection is project-specific, with no universal default.
Envelope Definition
Supersaturation kept within the metastable zone — typically 0.5–2× solubility gap, measured per API–solvent system.
Seeding & Cooling Curve
1–5 wt% seeds of the target form, seed PSD 10–50 µm, controlled ramp 0.1–0.5°C/min.
Scale-Up & PAT
Agitation tip speed 1–3 m/s, residence time and impurity profile; PAT monitoring of the batch trajectory at commercial scale.
Schematic, not to scale. Concentration / supersaturation increases upward; the metastable zone sits between the solubility and supersolubility curves. Metastable zone width is API- and solvent-specific (typical operating envelope 0.5–2× solubility gap) and is measured per system during process development.
No universal polymorph guarantee. Crystal form outcomes require project-level screening and DoE study — without a verified DoE, polymorph claims are speculative. EvapCryst engineers equipment that reproduces the recipe at commercial scale; we do not invent polymorph recipes.
GMP Compliance Baseline
Equipment-level compliance engineering built in from day one — these constraints cannot be added later.
| Compliance Element | EvapCryst Baseline | Notes & Conditions |
|---|---|---|
| Product-contact material | SS316L baseline | 3.1B EN 10204 certificates; full material traceability; Hastelloy C-276 for chlorinated solvent duty |
| Surface finish | Ra ≤ 0.4–0.8 µm | Product-contact surfaces, measured and documented; ≤ 0.4 µm polish typical for final API contact |
| Hygienic design | Slope ≥ 3° · no dead legs > 3D | Full drainability; sanitary clamp / ASME-BPE connections throughout |
| CIP | Spray balls / rotating jets | Coverage verified by riboflavin test; typical cleaning circuit 2% NaOH at 70°C + rinse |
| SIP | 121–134°C clean steam · 1.5–2.5 bar | Pressure-rated construction, sanitary venting and condensate management |
| Welding | Welder quals to ASME IX or equivalent | Weld records retained in the documentation package |
| Documentation | DQ / IQ / OQ outline + FAT protocol & report | Calibration traceable to NIST / NPL; PQ coordinated with the customer’s validation team |
Documentation scope is defined per project and per target market (FDA / EMA / NMPA).
Scope boundary: EvapCryst provides equipment-level GMP compliance support only. Drug Master File (DMF) submissions and pharmaceutical regulatory filings remain the responsibility of the pharmaceutical manufacturer.
Technology Routes for Pharma Duty
Typical first-pass routing — vacuum system selection alone spans three options by absolute pressure and vapor load.
Solvent Recovery Integration
The recovery loop is designed with the crystallizer, not bolted on after it — azeotrope behavior, energy and condensate quality decided together.
Materials Selection by Solvent System
The solvent — not the equipment catalog — picks the metallurgy. Chloride-bearing streams escalate from SS316L immediately.
Aqueous & Alcohol Systems
MeOH / EtOH / THF / toluene and water-based API duties.
- SS316L baseline for product contact
- Ra ≤ 0.4 µm polish for final API contact
- 3.1B EN 10204 material traceability
Chlorinated Solvents (DCM)
Dichloromethane CH₂Cl₂ — extraction solvent and mother-liquor duty.
- Aggressive Cl⁻ → Hastelloy C-276
- DCM–water azeotrope shapes the recovery design
- Regulated: VOC / Montreal Protocol handling
Saline Effluents & ZLD Brine
Pharmaceutical wastewater and mixed-solvent saline streams downstream of stripping.
- Hastelloy / Titanium by chloride profile
- Escalation confirmed by corrosion coupon testing in the scoping phase
- Trace-API pre-treatment ahead of the brine train
Related Solutions & Projects
EvapCryst organizes delivery around four solution lines — pharmaceutical projects most often combine S2 and S3.
Frequently Asked Questions
Standard GMP package includes: material certificates (3.1B EN 10204), weld records and welder qualifications, surface-finish measurement (Ra ≤ 0.4–0.8 µm for product-contact surfaces), pressure-test reports, slope-for-drainage verification, instrument calibration records, FAT protocol and report, and an equipment IQ/OQ outline. Full pharma commissioning (PQ) support is coordinated with the customer’s validation team. Documentation scope is defined per project and per target market (FDA / EMA / NMPA).
Polymorph control is decided at the process level — supersaturation profile (within metastable zone, typically 0.5–2× solubility gap), cooling ramp (0.1–0.5°C/min), seeding strategy (1–5 wt% of target form, seed PSD 10–50 µm), residence time, agitation intensity (tip speed 1–3 m/s) and impurity profile. The crystallizer is engineered to deliver the process envelope defined in the customer’s process development (DoE study). We do not invent polymorph recipes; we engineer equipment that reproduces the recipe at commercial scale. Without a verified DoE, polymorph claims are speculative.
API thermal degradation, racemization, color formation and impurity generation accelerate at atmospheric boiling (D&B > 0.1 at 420 nm within 8 h at 100°C for many APIs). Vacuum evaporation at 40–80°C and 30–200 mbar abs preserves product stability; the operating temperature is a process specification driven by API thermal data (DSC, TGA, forced-degradation study), not an engineering preference. Vacuum system selection follows duty: liquid ring pump for 50–200 mbar, dry screw for 1–50 mbar, steam ejector for very low pressure with high vapor load.
CIP requires spray balls or rotating jets covering all product-contact surfaces (coverage verified by riboflavin test), paired with cleaning-solution supply (typically 2% NaOH at 70°C + rinse), recovery and rinse circuits. SIP requires pressure-rated construction for 121–134°C clean steam at 1.5–2.5 bar, sanitary venting and condensate management. Both require slope-for-drainage (≥ 3° on all wetted surfaces), no dead legs longer than 3D, and sanitary clamp or ASME-BPE connections. These are engineering constraints from day one — they cannot be added later.
Discuss Your Pharmaceutical or Fine Chemical Project
Send us your API solvent system, thermal sensitivity, target polymorph and GMP documentation scope. Within two business days you will receive a feasibility assessment, simplified PFD and indicative scope.